심장 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cardiac biomarkers market size is expected to reach USD 65.85 Billion in 2034 from USD 23.50 Billion in 2025, growing at a CAGR of 12.13% during 2026-2034.The Cardiac Biomarkers market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases and the growing emphasis on early diagnosis and personalized treatment approaches. As healthcare providers seek to improve patient outcomes, the role of cardiac biomarkers in diagnosing and managing heart conditions has become increasingly critical. This market encompasses a range of biomarkers, including troponins, natriuretic peptides, and other proteins that provide valuable insights into cardiac health. The rising awareness of heart disease risk factors and the need for timely intervention are propelling the demand for advanced diagnostic tools in this sector.

Technological advancements are playing a pivotal role in the evolution of the Cardiac Biomarkers market, with innovations in point-of-care testing and laboratory diagnostics enhancing the speed and accuracy of cardiac assessments. The development of high-sensitivity assays and multiplex testing platforms is enabling healthcare providers to obtain comprehensive cardiac profiles quickly, facilitating informed decision-making. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, is expanding access to cardiac biomarker testing, particularly in underserved populations. As the market matures, companies that prioritize innovation and invest in research and development will likely capture a larger share of the growing demand.

Furthermore, the Cardiac Biomarkers market is increasingly influenced by regulatory developments and clinical guidelines that promote the use of biomarkers in cardiovascular care. As healthcare systems adopt evidence-based practices, the incorporation of cardiac biomarkers into routine clinical workflows is becoming more prevalent. This shift is driving investment in research initiatives aimed at discovering novel biomarkers and validating their clinical utility. As the focus on personalized medicine continues to grow, the demand for cardiac biomarkers that can guide treatment decisions and improve patient outcomes will expand. Companies that align their product offerings with clinical needs and regulatory requirements will be well-positioned to thrive in this dynamic market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Myocardial Muscle Creatine Kinase (CK-MB)
• Troponins (T and I)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

By Application

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

By Location of Testing

• Point of Care Testing
• Laboratory Testing

COMPANIES PROFILED

• F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., bioMerieux S.A., QuidelOrtho Corporation, Randox Laboratories Ltd., Becton, Dickinson and Company, Tosoh Corporation, PerkinElmer Inc., Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co., Ltd., Mindray Bio-Medical Electronics Co., Ltd., Fujirebio Holdings Inc., Beckman Coulter, Inc., Trinity Biotech plc

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIAC BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Myocardial Muscle Creatine Kinase (CK-MB) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Troponins (T and I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Myoglobin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Brain Natriuretic Peptide (BNPs) or NT-proBNP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Ischemia Modified Albumin (IMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIAC BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Myocardial Infarction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Congestive Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Acute Coronary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Atherosclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIAC BIOMARKERS MARKET: BY LOCATION OF TESTING 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Location Of Testing
• 6.2. Point of Care Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Laboratory Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIAC BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Location Of Testing
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Location Of Testing
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Location Of Testing
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Location Of Testing
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Location Of Testing
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CARDIAC BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche AG
  • 9.2.2 Siemens Healthineers AG
  • 9.2.3 Abbott Laboratories
  • 9.2.4 Thermo Fisher Scientific Inc
  • 9.2.5 Danaher Corporation
  • 9.2.6 Bio-Rad LaboratoriesInc
  • 9.2.7 BioMerieux S.A
  • 9.2.8 QuidelOrtho Corporation
  • 9.2.9 Randox Laboratories Ltd
  • 9.2.10 Becton, Dickinson And Company
  • 9.2.11 Tosoh Corporation
  • 9.2.12 PerkinElmer Inc
  • 9.2.13 Grifols S.A
  • 9.2.14 DiaSorin S.p.A
  • 9.2.15 Sysmex Corporation
  • 9.2.16 Lepu Medical Technology (Beijing) Co.Ltd
  • 9.2.17 Mindray Bio-Medical Electronics Co.Ltd
  • 9.2.18 Fujirebio Holdings Inc
  • 9.2.19 Beckman CoulterInc
  • 9.2.20 Trinity Biotech Plc